“…We believe that our review further elucidated this discussion. We found sufficient evidence that antipsychotic drugs were superior to phenobarbital for acute schizophrenia, yet evidence on the comparison with benzodiazepines was inconclusive because it was based on a single small trial (80 participants including the inert placebo arm) with large response rates in all arms (65% in inert placebo and benzodiazepines, 75% in chlorpromazine), small doses of chlorpromazine (about 150 mg/day), and the trial being sponsored by the company manufacturing the benzodiazepines (Merlis, Turner, & Krumholz, 1962; Siafis et al, 2019). We also want to add that in a small trial (not meeting the inclusion criteria of our review because it was conducted in stable patients) in 53 patients with schizophrenia, diazepam was comparable to fluphenazine and superior to placebo in preventing progression to a full relapse when used for early signs of exacerbation after the abrupt discontinuation of antipsychotics (Carpenter, Buchanan, Kirkpatrick, & Breier, 1999).…”